Recent 8-K filings for KOD
Highest-materiality recent filing
GLOW2 Phase 3 positive: Zenkuda meets primary endpoint, 62.5% vs 3.3% DRSS improvement, BLA accelerated
- 62.5% of Zenkuda patients achieved ≥2-step DRSS improvement vs 3.3% sham (p<0.0001).
- 85% risk reduction in sight-threatening complications (2.4% vs 15.8%, p=0.0001); 13.7% had ≥3-step DRSS improvement vs 0% sham.
-
Kodiak Sciences reports Q1 net loss $0.94/sh; Zenkuda GLOW2 positive, BLA planned
Cash $169.5M as of March 31, 2026, expected to fund operations into 2027.
-
Kodiak reports positive Phase 3 GLOW2 data for Zenkuda; plans accelerated BLA
Zenkuda Phase 3 GLOW2: 62.5% vs 3.3% achieved ≥2-step DRSS improvement (p<0.0001).
-
62.5% of Zenkuda patients achieved ≥2-step DRSS improvement vs 3.3% sham (p<0.0001).
-
Kodiak Sciences completes $184M public offering of 8M shares at $23/sh
Underwriters exercised in full the option for 1,043,478 additional shares, totaling 8,000,000 shares sold.
-
Kodiak Sciences Q3 net loss $61.5M ($1.16/share); cash $72M; Phase 3 trials on track
Net loss of $61.5M ($1.16/sh) vs $43.9M ($0.84/sh) in Q3 2024; R&D expenses rose to $50.5M from $31.9M on higher clinical and manufacturing activity.
-
Kodiak Sciences Q2 net loss $54.3M, cash $104.2M; pipeline milestones on track
Net loss of $54.3M ($1.03/share) vs $45.1M loss a year ago; R&D expenses rose to $42.8M.
-
Kodiak Sciences stockholders elect directors and ratify auditor at 2025 annual meeting
Elected Richard S. Levy, M.D. (29.2M for, 8.4M withheld) and Robert A. Profusek, J.D. (24.7M for, 12.9M withheld) as Class I directors.
-
Kodiak Sciences Q1 net loss $57.5M ($1.09/shr), cash $138.9M; pipeline on track for 2026 data
Net loss $57.5M ($1.09/shr) vs $43.0M ($0.82) in Q1 2024; non-cash stock comp $15.9M.
-
Kodiak Sciences reports Q4 net loss of $44.1M, cash $168.1M; pipeline trials on track
Cash and equivalents $168.1M at Dec 31, 2024; expected to fund operations into 2026.
-
Kodiak Sciences Q3 net loss $43.9M, cash $197.9M; provides pipeline updates
Net loss of $43.9M ($0.84/sh) vs $50.0M ($0.95/sh) in Q3 2023; cash $197.9M expected to fund operations into 2026.
-
Kodiak Sciences Q2 net loss $45.1M, cash $219.2M; three Phase trials enrolling
Net loss $45.1M ($0.86/sh) vs $80.2M ($1.53/sh) in Q2 2023; R&D expense down 52% to $32.5M.
-
Kodiak Sciences annual meeting results: Felix Baker receives ~32% withheld votes
Felix J. Baker re-elected with 27,555,597 for, 13,043,671 withheld (~32% of votes cast against).
-
Kodiak Sciences Q1 net loss $43M, cash $245.9M; advances tarcocimab and KSI-101 trials
Net loss of $43.0M ($0.82 per share) vs $70.8M ($1.35) in Q1 2023; includes $18.4M stock-based compensation.
-
Kodiak Sciences reports Q4 net loss of $59.5M; outlines Phase 3 plans for tarcocimab and KSI-501
Q4 2023 net loss $59.5M ($1.13/share) vs $70.4M ($1.35/share) in Q4 2022; R&D expenses fell to $46.6M.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.65 · Most common event earnings